Pulmatrix, Inc. · NASDAQ:PULM
Pulmatrix — Investor Presentation (June 2021)
17 slides from Pulmatrix's investor presentation, Jun 16, 2021
Slide 1: Pulmatrix – June 17, 2021
June 17, 2021 PULMATRIixX NASDAQ: PULM
Slide 2: Safe Harbor
Safe Harbor This presentation contains forward-looking statements. All statements other than statements of historical fact contained herein, including statements regarding our business plans or strategies, projected or anticipated benefits or other consequences of our plans or strategies, projected
Slide 3: Seasoned Management Team
Seasoned Management Team Deep expertise in respiratory diseases & drug delivery technology across all stages of development Rhonda Chicko — Strategic Advisor, Finance biotechnology and financial services sectors and VP of Finance at Editas Medicine Rusty Clayton, MD — Medical Director & Strategic Ad
Slide 4: Credentialed Board of Directors
Credentialed Board of Directors Board of Directors with extensive experience in public and private life sciences companies Michael J. Higgins — Chairman © Entrepreneur-in-residence at Polaris Partners and Board Member of Genocea, Voyager, Kindex, Madauder and Sea Pharmaceuticals © Former SVP, COO, a
Slide 5: PULM (NASDAQ) Investment Highlights
PULM (NASDAQ) Investment Highlights e Proprietary iSPERSE platform technology that seeks to optimize pharmacokinetics and pharmacology in respiratory and non-respiratory therapeutics e Ascalable platform with applicability across drug classes and dry-powder delivery devices to support pipeline devel
Slide 6: Pipeline Presents Multiple Potential Value Inflection Points
Pipeline Presents Multiple Potential Value Inflection Points iSPERSE™ enabled products span across multiple therapeutic categories Acute Exacerbations in jPhib Pri Datatlerpatea PUR1800_ Chronic Obstructive ata Anticipate NSKI Pulmonary Disease | Tox Studies 4 ys ' a (AECOPD) Tox Si S | 6- & 9-Month
Slide 7: PUR1800: $2.4B U.S. Peak Net Revenue Opportunity
PUR1800: jc ical $2.4B U.S. Peak Net Revenue Opportunity Vv) Za Prescriber Reported PUR1800 U Inhaled p38, Syk, Src Kinase Inhibitor with Potential for AECOPD iSPERSE Formulation of Janssen’s RV1162 Narrow Spectrum ~18M U.S. Annual Moderate to Severe AECOPD Episodes Kinase Inhibitor (NSKI) E | : PUR
Slide 8: First in Human Study of RV1162 (NSKI)
First in Human Study of RV1162 2 (NSKI) RV1162 Reduced p38 MAPK Phosphorylation RV1162 Reduced Sputum Neutrophils E § 200 7 os 25 —“~_, = a 22 20 = Qa > \ oe 15 5 15.0 EOD = Z= 10 Q £8 05 3 8. '0: 2 100 g & 00 Zz. 8 ax -05 a 50 = 9? 10 x = 7 15 0.0 + r r 1 -2.0 Sc d12 Sc2 d123 Sc d12 Sc2 123 Placebo
Slide 9: 28-Day GLP Toxicology Study Resulted in PUR1800 Improved Safety Margins
28-Day GLP Toxicology Study’ Resulted in PUR1800 Improved Safety Margins Relative to RV1162 iSPERSE Enabled Higher LUNG Dosing and Potentially Longer-term Dosing with PUR1800 500 ug > ~300 yg Data supports maximum PUR1800 Nominal Dose Lung Dose 4 nominal clinical dose of 550 yg and ability to delive
Slide 10: Phase 1b study bridging RV1162 to iSPERSE
ty study bridgin ion to iSPERSE Randomized, double-blind, 3-way crossover study; 3 Dose Groups (2 active, 1 placebo) with 15 pts. 14 days of daily dosing, with 28-day crossover and 28-day follow-up > -PUR1800 PUR1800 (250 1g) (500 pg) > PUR1800 1» PUR1800 eS oe : . PUR1800 . PURt800 rc, i >) a > to
Slide 11: PUR3100: $575M Peak Net Revenue Opportunity in the U.S.
\ £- PUR3100: $575M Peak Net Revenue Opportunity in the U.S. ¢ mig ™ ne ( > ) Forecast Build Overview Large market with significant unmet need in treatment of acute migraine % of triptan patients experiencing a suboptimal response 4 generic treatment % of patients ranking “starts to failures require
Slide 12: Inhaled DHE (MAP0004) Can Achieve Pain Freedom in Minutes
Inhaled DHE (MAP0004) Can Achieve Pain Freedom in < 30 Minutes Other acute migraine therapies have slower efficacy: triptan at ~1 hour and CGRP at ~2 hours % Patients @ Mean DHE Concentration (pg/mL) Plasma DHE (ng/mL) 80 100000 100.0 mMAPO004 ‘—*=MAP0004 250 ug/kg mPlacebo a see Actuation (N-6) e=P
Slide 13: PUR3100 Two-Part Ph1/Ph2 Study Intended to Demonstrate Proof of Concept
PUR3100 Two-Part Ph1/Ph2 Study Intended to Demonstrate Proof of Concept and Enable Pivotal Study PUR3100 Effectiveness Evaluated in Both Part 1 and Part 2 Phase 1 (Part 1) Interim Analysis Phase 2 (Part 2) Safety & PK Part 1-Safety/PK e Initial assessment of 32 patients of PK and acute safety in cli
Slide 14: Pulmazole: $1.5B U.S. Peak Net Revenue Opportunity
Pulmazole: $1.5B U.S. Peak Net Revenue Opportunity Overview Pulmatrix is in an ongoing contractual dispute with GRO, Cipla Technologies, LLC, Pulmatrix'’s development Sadie! partner, regarding the development of Pulmazole H sti | which may result in delays to our proposed clinical H 1st Line program
Slide 15: Pulmazole: Potential to Change Standard of Care for ABPA
Pulmazole: Potential to Change Standard of Care for ABPA Phase 1/1b study successfully set all endpoints Demonstrated safety and tolerability of Pulmazole administered up to 14 days J ~100—400 fold lower plasma exposure over 24 hours than expected with oral Sporanox ~5 cae escomre ~85 Bee eeberine 1
Slide 16: Phase 2b Study Intended to Demonstrate Proof of Concept
Phase 2b Study Intended to Demonstrate Proof of Concept in Patients with Asthma and ABPA Successful FDA Type C meeting enables Ph2b study potential start following the resolution of contractual dispute with Cipla? Patient Profile : Randomized 1} Patients (M/F, ages 18-80) with confirmed asthma and A
Slide 17: Pulmatrix is committed to the development and commercialization of novel medicines
PULMATRIiX is committed to the development and commercialization of novel and transformational medicines for patients all over the world, using our proprietary iSPERSE™ technology to optimally deliver both respiratory and non-respiratory therapies via the respiratory system.